Physician profile
Jacob Heuring
NPI 1427686583
$3,190.18
in general payments reported to CMS, 2019-2025
21 companies · $1,627 in 2025
The $1,627 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $509 · 2024: $1,054 · 2025: $1,627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,190.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $848.74 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $543.58 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $330.76 | 2023-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $267.89 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $240.57 | 2023-2025 | |
| Dexcom, INC. | $175.05 | 2023-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.74 | 2023-2025 | Jardiance, Tradjenta |
| Exact Sciences Corporation | $133.06 | 2023-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $86.06 | 2024-2025 | Voquezna |
| Pfizer INC. | $66.78 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $64.80 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $60.35 | 2024-2025 | Gemtesa |
| Amgen INC. | $35.66 | 2023-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $35.58 | 2024 | Spravato |
| Sanofi Pasteur INC. | $24.26 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $24.02 | 2025 | Capvaxive |
| Astellas Pharma US INC | $20.60 | 2024 | Veozah |
| Viatris Specialty LLC | $20.29 | 2025 | Yupelri |
| Si-Bone, INC. | $20.00 | 2025 | |
| Corcept Therapeutics | $19.25 | 2025 | Korlym |
| Abbott Laboratories | $16.14 | 2024 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Heuring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.